Inspira Announces 510(k) FDA Submission of INSPIRA ART100 Towards Commercialization
Portfolio Pulse from Benzinga Newsdesk
Inspira has announced the 510(k) FDA submission of INSPIRA ART100, with management estimating FDA clearance within approximately 6 months.
September 13, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inspira's FDA submission of INSPIRA ART100 could potentially lead to commercialization, which may positively impact the company's stock in the short term.
The FDA submission of INSPIRA ART100 is a significant step towards its commercialization. If approved, it could potentially increase the company's revenues and positively impact its stock price. However, the final impact will depend on the FDA's decision, which is expected in approximately 6 months.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100